Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 4Urinary Bladder Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Smoking Cessation 1Prostatic Hyperplasia 1Precancerous Conditions 1Papillomavirus Infections 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Condylomata Acuminata 1Barrett Esophagus 1

Interventions

Gemcitabine 79Cisplatin 56pembrolizumab 32Paclitaxel 28Carboplatin 24Docetaxel 19Radiotherapy 17Mitomycin 16Doxorubicin 15atezolizumab 14BCG Vaccine 14Nivolumab 13Cystectomy 13Filgrastim 11vinflunine 10Methotrexate 10Vinblastine 9Fluorouracil 95-aminolevulinic acid hexyl ester 9Sunitinib 7Early Intervention, Educational 7durvalumab 6avelumab 6Taxes 6Methods 6Cystoscopy 6Albumin-Bound Paclitaxel 6enfortumab vedotin 5Trastuzumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Urinary Bladder Neoplasms × polyphenon E × Clear all
NCT00088946 2020-07-31

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Completed
17 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00666562 2017-11-17

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡